GILD Gilead Sciences Inc. Loading...

From GILD earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
20:30
Aug 04 ◎
Andrew Dickinson CFO, Gilead Sciences, Inc. GILD Q2 FY26 call
Gilead raised its full-year sales guidance driven by strong HIV portfolio, Tredelvey, and Livdelzi performance, indicating a positive outlook and strong execution.
GILD
HIGH
20:30
May 07 ◎
Andrew Dickinson CFO, Gilead Sciences, Inc. GILD Q1 FY26 call
Management is confident in its commercial execution and the durability of its HIV franchise, including a raised full-year 2026 revenue guidance by $400 million and a $1 billion Yes2Go target.
GILD
HIGH
21:30
Feb 10 ◎
Joanna Mercier Chief Commercial and Corporate Affairs Officer at Gilead Sciences GILD Q4 FY25 call
Management's tone is bullish, with multiple catalysts (Yes2Go ramp, Trodelvy launches, anitocel) and reaffirmed discipline, positioning 2026 as a year of accelerated growth.
GILD
HIGH

About GILD Analyst Coverage

Buzzberg tracks GILD (Gilead Sciences Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Andrew Dickinson, Joanna Mercier.